Can You Split Retatrutide Twice Weekly? Schedule + Evidence

What Twice-Weekly Retatrutide Dosing Means

Retatrutide is normally given once weekly. A twice-weekly split takes that same weekly amount and breaks it into two equal injections spaced 3 to 4 days apart. Nothing about the total dose changes. If your weekly target is 8mg, you still receive 8mg across the week, just as two 4mg injections instead of one 8mg shot. The only thing that changes is the shape of the concentration curve over those seven days.

The Twice-Weekly Protocol in Practice

Concretely, the split halves whatever your current weekly dose happens to be. The total stays the same; the injection count doubles.

Who Discusses This Protocol, and Why

The people who talk about twice-weekly splitting are mostly on standard titration doses already, typically 4mg, 8mg, or 12mg weekly, and they are dealing with dose-dependent gastrointestinal side effects. Their goal is to smooth the weekly peak without dropping their total dose. That is a different motivation from sub-therapeutic exploration. The standard titration ladder is laid out in our retatrutide dosing guide, and nausea-specific strategies are covered in our nausea management guide. Keep in mind that retatrutide is investigational, so any self-directed change to its schedule is off-label by definition.

The Pharmacokinetic Rationale: Why a Twice-Weekly Split Dose of Retatrutide Is Logical

The whole case for twice-weekly dosing rests on one number: the half-life. Everything else, the spacing, the peak reduction, the steadier troughs, follows from it. The published pharmacokinetic data is what makes the protocol more than guesswork.

Modelled with the calculators' engine: half-life about 6 days, peak about 1 day after an injection (Phase 1 median), bioavailability assumed 80%, the same weekly total on both schedules, shown as a share of the once-weekly peak. Not trial data.

Retatrutide's Half-Life Is Approximately 6 Days

In the Phase 1b multiple-ascending-dose trial, the pharmacokinetics of LY3437943 were dose proportional and its half-life was approximately 6 days (Urva et al., Lancet, 2022). The discovery-to-proof-of-concept work reported the same profile and concluded it supported once-weekly dosing (Coskun et al., Cell Metabolism, 2022). A half-life this long has a practical consequence: a weekly dose does not fully clear before the next one lands. At day 7, roughly 44% of the previous dose is still present under simple decay (0.5 raised to 7 over 6), so the drug stacks dose over dose until it plateaus. Reaching that steady-state plateau takes about 4 weeks (estimated from the ~6-day half-life). The mechanics of that build-up are covered in detail in our retatrutide half-life and pharmacokinetics guide and visualized in the steady-state chart. The same stacking is why one skipped week does not empty the tank: the retatrutide missed dose calculator shows how far levels fall and how fast they rebuild.

The 3 to 4 Day Interval Math

Split a 7-day cycle into two roughly 3.5-day intervals and the half-life math gets favorable. At 3.5 days, about 0.58 half-lives have elapsed, so roughly two-thirds of the prior half-dose is still circulating when the next injection goes in (simple-decay arithmetic: 0.5 raised to 3.5 over 6 is about 0.67). Because each injection lands on top of a substantial residual level, the curve flattens. The single-injection peak drops, the troughs rise, and the swing between high and low narrows. Our calculator's pharmacokinetic model puts the steady-state peak reduction at about 15% for evenly spaced injections (about 13% on a Monday/Thursday pattern) and the peak-to-trough ratio at about 1.34 (1.42 Monday/Thursday), compared with about 1.97 for once-weekly dosing. The model puts a single dose's peak about 1 day after the injection, a median from Lilly's Phase 1 trials (in the Phase 1b study, blood was sampled mostly 12, 24, 48 and 72 hours after a dose); with a peak anywhere from half a day to a day and a half after the injection, the Monday/Thursday figure ranges from about 12% to 14%. Whatever the absorption speed, a 6-day half-life caps the once-weekly ratio at 2.24. These are modelled estimates, not figures measured in a clinical trial. You can run the numbers for your own dose level in the retatrutide pharmacokinetic calculator.

Why Not Three Times a Week or Daily?

More frequent injections smooth the curve further but with diminishing returns. In the same model, three times weekly (Monday/Wednesday/Friday) lowers the peak by about 15%, and daily dosing by about 21%, but means seven injections a week. Twice weekly is the most commonly adopted compromise because it halves the per-injection dose relative to once-weekly while only doubling, not septupling, the number of shots. It captures most of the smoothing benefit for the least added effort. For the full side-by-side of every frequency option, see our retatrutide microdosing schedules guide.

Video: Understanding the Retatrutide Half-Life

Because the twice-weekly rationale lives or dies on the half-life, it helps to see the concept explained visually. This short overview walks through what the approximately 6-day half-life means for how the drug behaves week to week.

How to Split a Retatrutide Dose: Practical Mechanics

Day Spacing: Monday/Thursday vs Other Combinations

Monday and Thursday gives you a 3-day gap followed by a 4-day gap. Monday and Friday flips that to 4 days then 3. Both work fine; the spacing is close enough to even that the curve stays smooth either way. What matters is consistency from week to week. Avoid lopsided patterns like Monday and Tuesday, where a 1-day gap is followed by a 6-day gap, because that recreates the single-dose peak the split was meant to soften and then leaves a long stretch with falling levels.

Drawing Half the Dose Accurately

Smaller draws leave less room for error, so accuracy matters more when you split. Your injection volume depends on how the vial was reconstituted, the milligrams in the vial, and the bacteriostatic water added. Rather than eyeballing or approximating units, enter your vial size, water and weekly dose in the retatrutide split dose calculator, which returns the volume in units for each injection of the split. This avoids the measurement drift that creeps in when you halve a dose by guesswork.

Injection Site Rotation on a Twice-Weekly Schedule

Injecting twice a week means twice the local tissue exposure, so rotation matters more. A simple pattern is Monday on the left side of the abdomen and Thursday on the right, or alternating to a thigh on one of the two days. Spreading the sites reduces local build-up and irritation. The full rotation map is in our retatrutide injection sites guide.

Does Split Dosing Reduce GI Side Effects? What the Data Says

The Tolerability Hypothesis

Gastrointestinal side effects in the retatrutide Phase 2 trial were dose-related and mostly mild to moderate. In the trial's posted results, nausea affected 45% of the 12 mg group, 60% of the 8 mg group that started at 4 mg and 17% of the 8 mg group that started at 2 mg, against 11% on placebo (ClinicalTrials.gov NCT04881760). The trial reported that these events were partially mitigated by a lower starting dose, 2 mg instead of 4 mg (Jastreboff et al., NEJM, 2023), which keeps early drug levels lower. Splitting a dose works the same way: a smaller per-injection amount means a lower single-dose peak, and potentially less gastrointestinal exposure at any one moment. That is a reasonable hypothesis built on the pharmacokinetics, but it stays a hypothesis until a trial tests it. None has tested twice-weekly dosing in retatrutide.

What the Evidence Does and Does Not Show

Be honest about where the evidence stands. No randomized trial of twice-weekly retatrutide is registered on ClinicalTrials.gov. What does exist: dose-proportional pharmacokinetics that make the modelling reliable, documented tolerability improvements from lower starting doses in Phase 2, and community reports. That combination supports the protocol as a reasoned, practitioner-discussed approach. It does not amount to a validated clinical recommendation, and it should not be presented as one.

Important Caveat: It Does Not Reduce Your Total Weekly Dose

This is the part people miss. A twice-weekly split keeps your total weekly dose identical to once-weekly dosing. If the real driver of your tolerability problem is the total amount of drug rather than the height of the peak, splitting will not fix it, and lowering the actual dose would be the relevant move instead. That distinction, peak versus total exposure, is exactly what our microdosing guide digs into.

Investigational Drug Warning: What You Need to Know

None of the pharmacokinetic reasoning in this article changes retatrutide's regulatory status. The math behind twice-weekly spacing is sound, but sound math is not clinical validation. Treat the protocol as what it is: a community approach informed by published pharmacokinetics, still waiting on the trial evidence that would confirm or refute its tolerability claims.